Finance

Lists
EYPT:NASDAQ
EyePoint Inc
၃.၄၄ US$
-၀.၄၃%
(-၀.၀၁၅) 1D
အောက် ၉, GMT-၄ ၁၁:၂၈:၅၄  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EYPT...
Open
၃.၄၄ US$
High
၃.၅၇ US$
Low
၃.၄၀ US$
Mkt. cap
၂၉.၇၀ ကုဋေ
Avg. vol.
၃.၅၂ သန်း
Volume
၃.၇၈ သိန်း
52-wk high
၁၉.၀၁ US$
52-wk low
၃.၀၅ US$
EPS
-၃.၇၄ US$
Beta
၁.၆၇
Shares outstanding
၈.၆၂ ကုဋေ
No. of employees
၂၁၄
Open
၃.၄၄ US$
High
၃.၅၇ US$
Low
၃.၄၀ US$
Mkt. cap
၂၉.၇၀ ကုဋေ
Avg. vol.
၃.၅၂ သန်း
Volume
၃.၇၈ သိန်း
52-wk high
၁၉.၀၁ US$
52-wk low
၃.၀၅ US$
EPS
-၃.၇၄ US$
Beta
၁.၆၇
Shares outstanding
၈.၆၂ ကုဋေ
No. of employees
၂၁၄
News stories
From web sources and news partners
Investing News Network
Investing News Network
·
ပြီးခဲ့သည့် ၂၄ မိနစ်
HackerOne Report Highlights Challenges of 'Exposure Debt': NYSE Content Update
marketscreener.com
marketscreener.com
·
ပြီးခဲ့သည့် ၁ နာရီ
IT Tech Packaging Gets NYSE Extension for Delayed SEC Filings
TradingView
TradingView
·
ပြီးခဲ့သည့် ၂၃ မိနစ်
How Versus Systems (NASDAQ: VS) Transforms Audience Engagement Through Gamification
Seeking Alpha
Seeking Alpha
·
ပြီးခဲ့သည့် ၇ မိနစ်
S&P 500’s top five stocks match market cap of bottom 434, Batnick says
Profile
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems and nanotechnology to drug delivery. pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency. QinetiQ continues to be a strategic partner. In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc. Wikipedia
About EyePoint Inc
CEO-
Employees၂၁၄
Founded၂၀၀၀
HeadquartersWatertown, မက်ဆာချူးဆက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Analyst ratings
Based on 12 analysts giving stock ratings to EYPT in the past 3 months
Buy
Buy
6
Hold
6
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for EYPT in the last 3 months.
Highest
Current ၃.၄၄ US$
၄၈.၀၀ US$ (+၁,၂၉၃.၃၂%)
Average
၂၀.၆၇ US$ (+၅၀၀.၀၀%)
Lowest
၄.၀၀ US$ (+၁၆.၁၁%)
Analyst
Recommendation
Action
Price target
Projected
Date
Debanjana Chatterjee
JonesTrading
Buy
Maintained
၂၀.၀၀ US$
+၄၈၀.၆%
10/07/2026
Yigal Nochomovitz
Citi
Buy
Maintained
၁၇.၀၀ US$
+၃၉၃.၅%
09/09/2026
Tara Bancroft
TD Cowen
Hold
Downgraded
၄.၀၀ US$
+၁၆.၁%
09/02/2026
Andreas Argyrides
Chardan Capital
Hold
Downgraded
၅.၀၀ US$
+၄၅.၁%
08/18/2026
Yi Chen
H.C. Wainwright
Hold
Downgraded
-
-
08/18/2026
Lisa Walter
RBC Capital
Hold
Downgraded
၅.၀၀ US$
+၄၅.၁%
08/17/2026
Yale Jen
Laidlaw
Buy
Maintained
၄၈.၀၀ US$
+၁,၂၉၃.၃%
08/17/2026
Faisal Khurshid
Jefferies
Buy
Maintained
၈.၀၀ US$
+၁၃၂.၂%
08/17/2026
Tessa Romero
J.P. Morgan
Hold
Downgraded
-
-
08/17/2026
Steven Seedhouse
Cantor Fitzgerald
Hold
Downgraded
-
-
08/17/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
၃၉.၀၀ US$
+၁,၀၃၂.၁%
08/17/2026
Annabel Samimy
Stifel Nicolaus
Buy
Initiated
၄၀.၀၀ US$
+၁,၀၆၁.၁%
07/16/2026
David Siffringer
Cantor Fitzgerald
Buy
Initiated
၄၇.၀၀ US$
+၁,၂၆၄.၃%
07/08/2026
Daniil Gataulin
Chardan Capital
Buy
Maintained
၆၅.၀၀ US$
+၁,၇၈၆.၈%
07/01/2026
Unknown Analyst
Jefferies
Buy
Maintained
၃၀.၀၀ US$
+၇၇၀.၈%
06/25/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
၆၈.၀၀ US$
+၁,၈၇၃.၉%
06/24/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
၆၈.၀၀ US$
+၁,၈၇၃.၉%
06/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၉.၆၆ သိန်း
၆.၂၀ သိန်း
၆.၉၆ သိန်း
၅.၀၇ သိန်း
Cost of goods sold
၄.၇၅ ကုဋေ
၅.၈၆ ကုဋေ
၇.၁၇ ကုဋေ
၈.၂၆ ကုဋေ
Cost of revenue
၄.၇၅ ကုဋေ
၅.၈၆ ကုဋေ
၇.၁၇ ကုဋေ
၈.၂၆ ကုဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁.၅၅ ကုဋေ
၁.၂၄ ကုဋေ
၁.၆၃ ကုဋေ
၁.၅၃ ကုဋေ
Operating expense
၁.၅၅ ကုဋေ
၁.၂၄ ကုဋေ
၁.၆၃ ကုဋေ
၁.၅၃ ကုဋေ
Total operating expenses
၆.၃၀ ကုဋေ
၇.၁၀ ကုဋေ
၈.၇၉ ကုဋေ
၉.၇၉ ကုဋေ
Operating income
-၆.၂၀ ကုဋေ
-၇.၀၃ ကုဋေ
-၈.၇၂ ကုဋေ
-၉.၇၄ ကုဋေ
Other non operating income
-
-
-
-
EBT including unusual items
-၅.၉၇ ကုဋေ
-၆.၇၄ ကုဋေ
-၈.၄၉ ကုဋေ
-၉.၄၅ ကုဋေ
EBT excluding unusual items
-၅.၉၇ ကုဋေ
-၆.၇၄ ကုဋေ
-၈.၄၉ ကုဋေ
-၉.၄၅ ကုဋေ
Income tax expense
-
၁.၈၆ သိန်း
-၅.၀၀ သောင်း
-
Effective tax rate
-
-၀.၂၈%
၀.၀၆%
-
Other operating expenses
-
-
-
-
Net income
-၅.၉၇ ကုဋေ
-၆.၇၆ ကုဋေ
-၈.၄၈ ကုဋေ
-၉.၄၅ ကုဋေ
Net profit margin
-၆,၁၈၃.၄၄%
-၁၀,၉၀၄.၆၈%
-၁၂,၁၈၈.၅၁%
-၁၈,၆၃၃.၁၄%
Earnings per share
-၀.၈၅
-၀.၈၁
-၀.၉၉
-၁.၀၉
Interest and investment income
၂.၂၉ သန်း
၂.၉၆ သန်း
၂.၃၄ သန်း
၂.၉၁ သန်း
Interest expense
-
-၃.၃၀ သောင်း
-
-
Net interest expenses
၂.၂၉ သန်း
၂.၉၂ သန်း
၂.၃၄ သန်း
၂.၉၁ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၆.၁၄ ကုဋေ
-၆.၉၆ ကုဋေ
-၈.၆၆ ကုဋေ
-၉.၆၇ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ